Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL versus PENICILLIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL versus PENICILLIN 2.
BACTOCILL vs PENICILLIN-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
None Documented
None Documented
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic